利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.023 秒)

    CL-1957B antibiotic compound and its production
    2.
    发明授权
    CL-1957B antibiotic compound and its production 失效
    CL-1957B抗生素复方及其生产

    公开(公告)号：US4918100A

    公开(公告)日：1990-04-17

    申请号：US763577

    申请日：1985-08-08

    申请人： Gerard C. Hokanson ,  John P. Schaumberg ,  James C. French ,  Josefino B. Tunac

    发明人： Gerard C. Hokanson ,  John P. Schaumberg ,  James C. French ,  Josefino B. Tunac

    IPC分类号： C07D309/22 ,  C07D309/32 ,  C12P17/06

    CPC分类号： C12R1/01 ,  C07D309/22 ,  C07D309/32 ,  C12P17/06

    摘要： A purified isolate of an actinomycete identified as ATCC 39366 is capable of producing the anti-microbial compound CL-1957B which also exhibits antitumor properties.The antimicrobial compound CL-1957B is produced by cultivating isolate ATCC 39366 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantial quantity of the CL-1957B compound is produced, and subsequently isolating the compound.The antibiotic compound CL-1957B, its pharmaceutically acceptable salts, the pharmaceutical compositions comprising this substance together with a pharmaceutically acceptable carrier is also disclosed, as are methods of treating microbial infections and tumors in mammals, employing these pharmaceutical compositions.

    摘要翻译： 确定为ATCC 39366的放线菌的纯化分离物能够生产也具有抗肿瘤性质的抗微生物化合物CL-1957B。 抗微生物化合物CL-1957B是通过在需氧条件下培养含有可同化碳源和氮源的培养基中分离的ATCC 39366产生的，直到产生大量的CL-1957B化合物，然后分离该化合物。 还公开了抗生素化合物CL-1957B及其药学上可接受的盐，包含该物质的药物组合物和药学上可接受的载体，以及使用这些药物组合物治疗哺乳动物的微生物感染和肿瘤的方法。

    CL-1957A antibiotic compound
    4.
    发明授权
    CL-1957A antibiotic compound 失效
    CL-1957A抗生素化合物

    公开(公告)号：US4771070A

    公开(公告)日：1988-09-13

    申请号：US912684

    申请日：1986-09-26

    申请人： Gerard C. Hokanson ,  John P. Schaumberg ,  James C. French ,  Josefino B. Tunac

    发明人： Gerard C. Hokanson ,  John P. Schaumberg ,  James C. French ,  Josefino B. Tunac

    IPC分类号： C07D309/22 ,  C12P17/06 ,  A61K31/365 ,  C07D309/38

    CPC分类号： C07D309/22 ,  C12P17/06

    摘要： A purified isolate of an actinomycete identified as ATCC 39366 is capable of producing the anti-microbial compound CL-1957A which also exhibits antitumor properties.The antimicrobial compound CL-1957A is produced by cultivating isolate ATCC 39366 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantial quantity of the CL-1957A compound is produced, and subsequently isolating the CL-1957A compound.The antibiotic compound CL-1957A and pharmaceutical compositions comprising this substance together with a pharmaceutically acceptable carrier is also disclosed, as are methods of treating microbial infections and tumors in mammals, employing these pharmaceutical compositions.

    摘要翻译： 确定为ATCC 39366的放线菌的纯化分离物能够产生也具有抗肿瘤性质的抗微生物化合物CL-1957A。 抗微生物化合物CL-1957A是通过在需氧条件下培养含有可同化碳源和氮源的培养基中分离的ATCC 39366产生的，直到产生大量的CL-1957A化合物，然后分离出CL-1957A化合物。 还公开了抗生素化合物CL-1957A和包含该物质的药物组合物与药学上可接受的载体，以及使用这些药物组合物治疗哺乳动物的微生物感染和肿瘤的方法。

    CL-1577-B.sub.4 compound, its production and use
    7.
    发明授权
    CL-1577-B.sub.4 compound, its production and use 失效
    CL-1577-B4化合物，其生产和使用

    公开(公告)号：US4661353A

    公开(公告)日：1987-04-28

    申请号：US804411

    申请日：1985-12-04

    申请人： John H. Wilton ,  Gerard C. Hokanson ,  James C. French

    发明人： John H. Wilton ,  Gerard C. Hokanson ,  James C. French

    IPC分类号： C07G11/00 ,  A61K35/74 ,  A61P31/04 ,  A61P35/00 ,  C12N1/20 ,  C12P1/06 ,  C12R1/01 ,  C12R1/04

    CPC分类号： C12P1/06

    摘要： CL-1577-B.sub.4 compound is derived by the solvolysis under anhydrous conditions of either CL-1577A compound of CL-1577B compound, obtained from the fermentative action of a purified strain of Actinomycete designated ATCC 39363 under aerobic conditions.CL-1577-B.sub.4 compound is a potent antimicrobial agent, possessing activity against a number of gram-positive and gram-negative bacteria, yeasts, and fungi. In addition, the compound exhibits in vivo activity against the P388 murine leukemia cell line and in vitro activity against the L1210 murine leukemia cell line.A method of making the compound as well as pharmaceutical compositions and methods for their use are also disclosed.

    摘要翻译： CL-1577-B4化合物是通过在无氧条件下溶解分解得到的CL-1577B化合物的CL-1577B化合物，其由在有氧条件下命名为ATCC 39363的纯化的放线菌菌株的发酵作用获得。 CL-1577-B4化合物是一种有效的抗微生物剂，具有抗多种革兰氏阳性和革兰氏阴性细菌，酵母菌和真菌的活性。 此外，该化合物对P388鼠白血病细胞系具有体内活性，对L1210鼠白血病细胞系具有体外活性。 还公开了制备该化合物的方法以及其使用的药物组合物和方法。

    CL-1577-B.sub.4 compound, its production and use
    8.
    发明授权
    CL-1577-B.sub.4 compound, its production and use 失效
    CL-1577-B4化合物，其生产和使用

    公开(公告)号：US4594248A

    公开(公告)日：1986-06-10

    申请号：US712294

    申请日：1985-03-15

    申请人： John H. Wilton ,  Gerard C. Hokanson ,  James C. French

    发明人： John H. Wilton ,  Gerard C. Hokanson ,  James C. French

    IPC分类号： C07G11/00 ,  A61K35/74 ,  A61P31/04 ,  A61P35/00 ,  C12N1/20 ,  C12P1/06 ,  C12R1/01 ,  C12R1/04

    CPC分类号： C12P1/06

    摘要： CL-1577-B.sub.4 compound is derived by the solvolysis under anhydrous conditions of either CL-1577A compound or CL-1577B compound, obtained from the fermentative action of a purified strain of Actinomycete designated ATCC 39363 under aerobic conditions.CL-1577-B.sub.4 compound is a potent antimicrobial agent, possessing activity against a number of gram-positive and gram-negative bacteria, yeasts, and fungi. In addition, the compound exhibits in vivo activity against the P388 murine leukemia cell line and in vitro activity against the L1210 murine leukemia cell line.A method of making the compound as well as pharmaceutical compositions and methods for their use are also disclosed.

    摘要翻译： CL-1577-B4化合物通过在无氧条件下的溶剂分解得到，CL-1577A化合物或CL-1577B化合物是在有氧条件下从称为ATCC 39363的纯化的放线菌菌株的发酵作用获得的。 CL-1577-B4化合物是一种有效的抗微生物剂，具有抗多种革兰氏阳性和革兰氏阴性细菌，酵母菌和真菌的活性。 此外，该化合物对P388鼠白血病细胞系具有体内活性，对L1210鼠白血病细胞系具有体外活性。 还公开了制备该化合物的方法以及其使用的药物组合物和方法。

    Guanine-N.sup.7 -oxide
    10.
    发明授权
    Guanine-N.sup.7 -oxide 失效
    鸟嘌呤-N7氧化物

    公开(公告)号：US4551529A

    公开(公告)日：1985-11-05

    申请号：US539517

    申请日：1983-10-06

    申请人： Donald L. Kern ,  Gerard C. Hokanson ,  James C. French

    发明人： Donald L. Kern ,  Gerard C. Hokanson ,  James C. French

    IPC分类号： A61K31/52 ,  A61K31/522 ,  A61P31/04 ,  A61P35/00 ,  C07D473/18 ,  C12P17/18 ,  C12R1/01 ,  C12R1/04

    CPC分类号： C07D473/18 ,  C12P17/182 ,  Y10S435/826

    摘要： A purified isolate of an actinomycete identified as ATCC 39364 is capable of producing the antimicrobial/antitumor compound 2-amino-1,9-dihydro-6H-purine-6-one-7-oxide, commonly known as guanine-N.sup.7 -oxide.Guanine-N.sup.7 -oxide is produced by cultivating isolate ATCC 39364 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantial amount of the compound is produced and thereafter isolating the compound.The antibiotic/antitumor compound guanine-N.sup.7 -oxide and pharmaceutical compositions comprising this compound or one of its pharmaceutically acceptable salts together with a pharmaceutically acceptable carrier are also disclosed as is a method of treating microbial infections in a mammal or of treating tumors in a mammal.

    摘要翻译： 确定为ATCC 39364的放线菌的纯化分离物能够产生通常称为鸟嘌呤-N7氧化物的抗微生物/抗肿瘤化合物2-氨基-1,9-二氢-6H-嘌呤-6-酮-7-氧化物。 鸟嘌呤-N7氧化物是通过在需氧条件下培养分离物ATCC 39364，在含有可吸收的碳源和氮源的培养基中培养，直到产生大量的化合物，然后分离化合物。 还公开了抗生素/抗肿瘤复合物鸟嘌呤-N7氧化物和包含该化合物或其药学上可接受的盐的一种药物组合物与药学上可接受的载体的药物组合物，一种治疗哺乳动物微生物感染或治疗哺乳动物肿瘤的方法 。